Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Immix Biopharma has not disclosed the timing of its earnings release, so the Day 0 and Day +1 moves should be interpreted with caution—Day 0 may reflect anticipation or intraday reaction depending on whether results are released before the open, after the close, or during market hours.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-08-07 | -$0.34 (-3.38%) | $1.06 (10.54%) | +$0.41 (+4.22%) | $0.67 (6.89%) |
| 2026-05-07 | -$0.78 (-7.56%) | $0.79 (7.66%) | +$0.21 (+2.20%) | $0.90 (9.43%) |
| 2026-03-25 | +$0.34 (+3.97%) | $0.63 (7.35%) | -$0.19 (-2.13%) | $1.40 (15.71%) |
| 2025-11-07 | +$0.12 (+3.96%) | $0.33 (10.89%) | +$0.09 (+2.86%) | $0.35 (11.11%) |
| 2025-08-08 | +$0.00 (+0.00%) | $0.12 (4.88%) | -$0.07 (-2.93%) | $0.24 (10.04%) |
| 2025-05-08 | +$0.02 (+1.18%) | $0.20 (9.43%) | -$0.06 (-2.56%) | $0.18 (8.37%) |
| 2025-03-24 | +$0.02 (+1.11%) | $0.05 (2.78%) | +$0.03 (+1.65%) | $0.15 (8.25%) |
| 2024-11-12 | -$0.05 (-2.82%) | $0.09 (5.08%) | -$0.15 (-8.72%) | $0.20 (11.34%) |
| Avg Abs Move | 3.00% | 7.33% | 3.41% | 10.14% |
Immix has exhibited volatile post-earnings price action, with an average absolute Day 0 move of 3.00% and Day +1 move of 3.41%. The most dramatic reaction came in May 2026, when the stock dropped 7.56% on earnings day, though it recovered with a 2.20% gain the following session. The March 2026 report saw a 3.97% Day 0 gain followed by a 2.13% pullback, illustrating the stock's tendency to reverse initial moves.
The Day 0 range has averaged 7.33%, while the Day +1 range has been wider at 10.14%, suggesting heightened volatility in the session following the release. The November 2024 report saw an 8.72% decline on Day +1, the largest single-session drop in the dataset. Given the upcoming ASH presentation and the company's progress toward a BLA filing, investors should expect elevated volatility around this release, particularly if management provides new guidance on the regulatory timeline or commercial strategy.
Part 3: What Analysts Are Saying
Analysts maintain a strongly bullish stance on Immix Biopharma, with 6 Strong Buys, 1 Moderate Buy, and 1 Hold among the 8 analysts covering the stock. The consensus rating of 4.63 reflects high conviction in the company's clinical and commercial prospects.
The average price target of $24.29 implies 201% upside from the current $8.07 price, with a range from $19.00 to $30.00. The wide spread reflects differing views on execution risk and valuation methodology—bulls emphasize NXC-201's best-in-class efficacy and the large addressable market, while more conservative analysts factor in dilution from recent equity raises and the challenges of launching a complex CAR-T therapy in a rare disease.
Analyst sentiment has remained unchanged over the past month, with the same rating distribution and target range. The stability suggests the Street is waiting for the upcoming ASH presentation and Q3 earnings to reassess the investment thesis. The consensus view is that Immix has de-risked the clinical profile of NXC-201, but the path to profitability hinges on successful regulatory approval, reimbursement negotiations, and commercial execution in a fragmented rare-disease market.
Part 4: Technical Picture
The Barchart Technical Opinion for Immix Biopharma has deteriorated sharply, moving from an 8% Sell signal a month ago to a 40% Sell last week and now a 72% Sell today. The rapid shift reflects mounting technical pressure as the stock has broken below key support levels.
Timeframe Analysis:
- Short-term (100% Sell): The near-term outlook is decisively bearish, with all short-term indicators pointing to downside momentum
- Medium-term (50% Sell): The intermediate timeframe shows moderate selling pressure, suggesting consolidation or further weakness ahead
- Long-term (50% Sell): The longer-term trend also leans negative, indicating structural weakness beyond near-term volatility
Trend Characteristics: The signal strength is Average with the Strongest directional bias, indicating that while the magnitude of the trend is moderate, the consistency of the bearish signals is pronounced—a setup that often precedes continued downside or a sharp reversal if catalysts emerge.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $8.34 | 50-Day MA | $9.94 |
| 10-Day MA | $7.95 | 100-Day MA | $10.40 |
| 20-Day MA | $8.09 | 200-Day MA | $9.61 |
The stock is trading at $8.07, below all major moving averages except the 10-day ($7.95). It sits below the 5-day ($8.34), 20-day ($8.09), 50-day ($9.94), 100-day ($10.40), and 200-day ($9.61) averages, a configuration that signals a sustained downtrend. The 50-day and 100-day averages are particularly concerning, as the stock has fallen more than 18% and 22% below those levels, respectively.
The technical setup heading into earnings is cautionary. The stock is in a clear downtrend with deteriorating momentum, and the 72% Sell signal suggests limited near-term support. However, the upcoming ASH presentation and potential positive commentary on the BLA timeline could serve as catalysts for a reversal. Traders should watch the $7.95 level (10-day MA) as immediate support and the $8.34 level (5-day MA) as initial resistance. A break above the 20-day average at $8.09 would be the first sign of technical stabilization.